NPM1 and acute myeloid leukemia: Moreover, there was a wide range of prevalence estimates for FLT3‐ITD and NPM1 co‐mutations in AML, from 0.9%–28.0%, with the prevalence of the NPM1 mutation among patients with known FLT3‐ITD mutations ranging from 9.0%–60.0%.